4 results on '"Moenig, Stefan"'
Search Results
2. Two decades of gastric and gastroesophageal junction cancer surgery.
- Author
-
Plum, Patrick S., Pamuk, Aylin, Barutcu, Atakan G., Mallmann, Christoph, Niesen, Emanuel, Berlth, Felix, Zander, Thomas, Chon, Seung-Hun, Moenig, Stefan P., Quaas, Alexander, Bruns, Christiane J., Hoelscher, Arnulf H., and Alakus, Hakan
- Subjects
- *
ESOPHAGOGASTRIC junction , *ONCOLOGIC surgery , *GASTROINTESTINAL surgery , *NEOADJUVANT chemotherapy , *GASTRIC bypass , *SURVIVAL rate , *TUMOR classification - Abstract
Purpose: Diagnosis and treatment of gastric and gastroesophageal junction cancer have undergone many critical changes during the last two decades. We addressed the question of how clinical reality outside of clinical trials has changed for gastric and gastroesophageal junction cancer patients in a European center for upper gastrointestinal surgery. Methods: In this retrospective cohort study, patients undergoing (sub)total gastrectomy for gastric or gastroesophageal junction adenocarcinoma between 1996 and 2017 in a tertiary upper gastrointestinal center were included. The time was divided into a) before (1996–2006) (pre-CTx) and b) after (2006–2017) (CTx) the MAGIC trial. Data were comprehensively analyzed for demographics, tumor stage, perioperative treatment, surgery, histopathology, and survival rates (SR). Results: 737 patients (32% female) underwent gastrectomy, 255 patients in the pre-CTx era and 482 patients in the CTx era. The median age was 65 years and the median follow-up was 27.5 months for surviving patients. Around 16.9% of patients received neoadjuvant treatment in the pre-CTx era versus 46.3% in the CTx era. The 3-year survival rate (3-YSR) was 46.4% in the pre-CTx and 60.9% in the CTx era (p < 0.001). For pretreated patients, 3-YSR was 39.0% (pre-CTx) versus 55.3% (CTx) (p = 0.168). Survival rate (SR) for locally advanced tumor stages (cT3/cT4) was higher when neoadjuvant therapy was administered (3-YSR: 56.7% vs 40.6%; p = 0.022). There were no significant differences according to sex (p = 0.357), age (p = 0.379), pT category (p = 0.817), pN stage (p = 0.074), cM stage (p = 0.112), Laurén classification (p = 0.158), and SRs (3-YSR: 60.3% vs 59.4%; p = 0.898) between the MAGIC and FLOT regimens. Conclusions: Survival rates have dramatically improved for gastric cancer patients during the last two decades. MAGIC and FLOT regimens showed similar results in the postsurgical follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Histological Grading in Gastric Cancer by Ming Classification: Correlation with Histopathological Subtypes, Metastasis, and Prognosis.
- Author
-
Luebke, Thomas, Baldus, Stephan E., Grass, Guido, Bollschweiler, Elfriede, Thiele, Jürgen, Dienes, Hans-Peter, Hoelscher, Arnulf H., and Moenig, Stefan P.
- Subjects
- *
STOMACH cancer , *HISTOLOGY , *HISTOPATHOLOGY , *METASTASIS , *PROGNOSIS , *GASTRECTOMY - Abstract
The aim of this prospective study was to analyze Ming's classification in correlation with other currently used classification systems of gastric cancer. In addition, we wanted to define the prognostic significance of the Ming classification system. The present study analyzed material of 117 patients with gastric carcinoma who underwent D2-gastreotomy with curative intent. All specimens were catagorized according to International Union Against Cancer (UICC) classification, World Health Organization (WHO) classification, Borrmann classification, Lauren classification, Goseki classification, Ming classification, and tumor differentiation. For analysis of correlation between the classification systems, the correlation coefficient according to Spearman was calculated. The survival curves have been calculated according to the Kaplan-Meier method. According to the Ming classification, 38.5% of the carcinomas exhibited an expanding growth pattern, and 61.5% of specimens showed an infiltrating growth pattern. The subtypes according to the Ming and Lauren classification correlated significantly (P « 0,001). WHO classification (P « 0.001), tumor differentiation (P « 0.001), and Goseki classification (P « 0.001), as well as the macroscopic classification of Borrmann (P « 0.001) and the pT and pN categories of the UICC classification exhibited a highly significant correlation with the Ming classification (P « 0.001 and 0.001, respectively). Median overall survival was 31.3 months. In Kaplan-Meier analysis, the 3-year survival rates were lower in the infiltrative tumor type when compared to the expansive tumor type according to Ming (P = 0,0847). In multivariate analysis, only the UICC system presented as an independent prognostic factor in multivariate analysis (P« 0.001), This study shows that the Ming classification correlates significantly with the currently used classification systems for gastric cancer and with the UICC staging system, especially, the pT and pN category. The 3-year survival rates were lower in the infiltrative tumor type than in the expansive tumor type according to Ming. However, the Ming classification is not an independent prognostic factor. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
4. Blood-Based Multi-Cancer Detection Using a Novel Variant Calling Assay (DEEPGEN TM): Early Clinical Results.
- Author
-
Ris, Frederic, Hellan, Minia, Douissard, Jonathan, Nieva, Jorge J., Triponez, Frederic, Woo, Yanghee, Geller, David, Buchs, Nicolas C., Buehler, Leo, Moenig, Stefan, Iselin, Christophe E., Karenovics, Wolfram, Petignat, Patrick, Lam, Giang Thanh, Undurraga Malinervo, Manuela, Tuttle, Rebecca, Ouellette, James, Bose, Debashish, Ismail, Nael, and Toso, Christian
- Subjects
- *
DNA , *CONFIDENCE intervals , *EARLY detection of cancer , *CASE-control method , *MACHINE learning , *CANCER patients , *TUMOR classification , *LONGITUDINAL method , *ALGORITHMS ,BODY fluid examination - Abstract
Simple Summary: Cancer remains a worldwide concern with significant burdens on the population and healthcare systems. Studies have shown that early detection is paramount in positive patient outcomes, although the standard of care screening is limited to a few cancers. When a tumor cell dies, it releases DNA into the bloodstream. This cell-free DNA can be extracted, and specific mutations identified. Technologies based on this principle are gaining popularity amongst physicians for cancer patients to inform personalized treatment. Additionally, if platforms are sensitive enough, blood-based multi-cancer screening can be performed. DEEPGENTM is a next-generation sequencing platform that has been optimized for early cancer detection. This study is a preliminary analysis of cancer detection rates across seven cancers using the DEEPGENTM platform. This is an early clinical analysis of the DEEPGENTM platform for cancer detection. Newly diagnosed cancer patients and individuals with no known malignancy were included in a prospective open-label case-controlled study (NCT03517332). Plasma cfDNA that was extracted from peripheral blood was sequenced and data were processed using machine-learning algorithms to derive cancer prediction scores. A total of 260 cancer patients and 415 controls were included in the study. Overall, sensitivity for all cancers was 57% (95% CI: 52, 64) at 95% specificity, and 43% (95% CI: 37, 49) at 99% specificity. With 51% sensitivity and 95% specificity for all stage 1 cancers, the stage-specific sensitivities trended to improve with higher stages. Early results from this preliminary clinical, prospective evaluation of the DEEPGENTM liquid biopsy platform suggests the platform offers a clinically relevant ability to differentiate individuals with and without known cancer, even at early stages of cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.